Form 4: Protara Therapeutics CFO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Patrick Fabbio, CFO of Protara Therapeutics, sold 3,061 shares of common stock on January 21, 2025, to cover income tax obligations related to a restricted stock unit award.
Summary
- On January 21, 2025, Patrick Fabbio, the Chief Financial Officer of Protara Therapeutics, sold 3,061 shares of the company's common stock.
- The sale was executed at a price of $4.76 per share.
- This transaction was conducted to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to Mr. Fabbio on January 19, 2024.
- Following the transaction, Mr. Fabbio directly owns 18,939 shares of Protara Therapeutics.
Sentiment
Score: 6
Explanation: The document is neutral. It simply reports a stock sale by an executive to cover tax obligations, which is a common occurrence. There's no indication of positive or negative sentiment towards the company's prospects.
Industry Context
This is a routine Form 4 filing, which is common when company executives sell shares, especially to cover tax obligations related to stock awards. It doesn't necessarily indicate a negative outlook on the company.
Key Dates
| Date | Description |
|---|---|
| 01/19/2024 | Date of Restricted Stock Unit Award grant to Patrick Fabbio |
| 01/21/2025 | Date of stock sale by Patrick Fabbio |
| 01/23/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.